Gilead’s HIV sales hit $4.7B in Q3, first six-month PrEP approval planned in 2025

Gilead says it’s gaining clinical momentum with plans to grow its HIV franchise and nab an approval for an every-six-month pre-exposure prophylaxis (PrEP) approval.

Gilead’s third-quarter revenue total of $7.1 billion was driven by increased sales in HIV and oncology, the company said. In HIV products alone, Gilead pulled in…
Click here to view original post